For research use only. Not for therapeutic Use.
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex[1].
Tesidolumab (LFG316) possesses a half-life in humans of approximately 9 days. Tesidolumab (LFG316) binds to a distinct epitope to that of eculizumab and ravulizumab, distant to Arg 885[1].
| Catalog Number | I042400 |
| CAS Number | 1531594-08-7 |
| Purity | ≥95% |
| Reference | [1]. Jun-Ichi Nishimura, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2022 Jun 1;107(6):1483-1488. |
